159 related articles for article (PubMed ID: 36698436)
1. A Primary Lung and Breast Cancer Patient with Germline
Li D; Liu X; Cui S; Yang D; Zhu Y; Pan E; Yang P; Dai Z
Onco Targets Ther; 2023; 16():17-22. PubMed ID: 36698436
[TBL] [Abstract][Full Text] [Related]
2. Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation.
Guo T; Zhu L; Li W; Lin R; Ding Y; Kang Q; Shao L; Li C; Pan X
Lung Cancer; 2021 Nov; 161():94-97. PubMed ID: 34555730
[TBL] [Abstract][Full Text] [Related]
3. Identification of
Wang T; Zheng Q; Deng C; Li X; Huang J; Fan J; Huang B; Zhang J; Chang X; Nie X
Respir Med Case Rep; 2024; 50():102051. PubMed ID: 38868164
[TBL] [Abstract][Full Text] [Related]
4. Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family.
Gabriel L; McVeigh T; Macmahon S; Avila Z; Donovan L; Hunt I; Draper A; Minchom A; Popat S; Davidson M; Bhosle J; Milner Watts C; Hubank M; Yuan L; O'Brien M
Lung Cancer; 2024 May; 191():107543. PubMed ID: 38569279
[TBL] [Abstract][Full Text] [Related]
5. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
6. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
7. Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With
Lin X; Peng M; Chen Q; Yuan M; Chen R; Deng H; Deng J; Liu O; Weng Y; Chen M; Zhou C
Front Oncol; 2021; 11():774156. PubMed ID: 34869019
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report.
He SY; Lin QF; Chen J; Yu GP; Zhang JL; Shen D
World J Clin Cases; 2021 Feb; 9(6):1329-1335. PubMed ID: 33644199
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
[TBL] [Abstract][Full Text] [Related]
10. The broad spectrum of tyrosine kinase inhibitors. Treatment of a rare
Cui J; Tabbara S; Chadha J
SAGE Open Med Case Rep; 2023; 11():2050313X231196663. PubMed ID: 37663150
[No Abstract] [Full Text] [Related]
11. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnosis and clinical outcome of a lung cancer patient with
Yang D; Han X; Li D; Cui S; Liu S; Wu X; Dai Z
Am J Transl Res; 2020; 12(10):6689-6693. PubMed ID: 33194065
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Floc'h N; Lim S; Bickerton S; Ahmed A; Orme J; Urosevic J; Martin MJ; Cross DAE; Cho BC; Smith PD
Mol Cancer Ther; 2020 Nov; 19(11):2298-2307. PubMed ID: 32943544
[TBL] [Abstract][Full Text] [Related]
15. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
16. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review.
Lin R; Chen R; Chen Z; Hu L; Guo W; Zhang Z; Lin L; Chen H
Front Oncol; 2021; 11():731572. PubMed ID: 34540698
[TBL] [Abstract][Full Text] [Related]
18. A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report.
Shan CG; Wang H; Lin T; Liu D; Wen L; Chen ZJ; Zhen JJ; Lai MY; Zhang L; Zou X; Hong WP; Cai LB
Ann Palliat Med; 2021 May; 10(5):5897-5901. PubMed ID: 33977730
[TBL] [Abstract][Full Text] [Related]
19. [Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report].
Wang X; Dong Y; Liang T; Zhang X; Ma K; Cui Y
Zhongguo Fei Ai Za Zhi; 2015 Sep; 18(9):592-8. PubMed ID: 26383985
[TBL] [Abstract][Full Text] [Related]
20. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]